Effect of 1% Povidone Iodine Mouthwash/Gargle, Nasal and Eye Drop in COVID-19 patient

• Published in: Bioresearch communications Vol. 7; no. 1; pp. 919 - 923
• Main Authors: Choudhury, Md Iqbal Mahmud, Shabnam, Nilufar, Ahsan, Tazin, Kabir, Md Saiful, Md Khan, Rashed, Ahsan, SM Abu
• Format: Journal Article
• Language: English
• Published: 23.06.2021
• ISSN: 2411-0485; 2411-0272
• DOI: 10.3329/brc.v7i1.54245

Background: The sudden onset of COVID-19 began in late 2019 caused by a novel coronavirus (SARS-COV2) and on 11th March, WHO declared it to have developed pandemic status. There is still no specific treatment and vaccine available for COVID-19; causing wide spread health problem and concern of the globe. Povidone iodine (PVP-I) is an antiseptic that has been used for over 150 years. It is already proved that different concentration of PVP-I can deactivate COVID-19 virus. Methodology: In this randomized controlled clinical trial, out of 1113 patients 606 patients were enrolled and divided in 2 groups by randomization after taken consents. In Gr-A, 303 patients underwent mouthwash/gargle, nasal drops and eye drops with 1% povidone iodine 4 hourly for 4 weeks as well as symptomatic treatment according to need. In Gr-B 303 patients were advised mouthwash/gargle, nasal cavity and eye wash with lukewarm water 4 hourly for 4 weeks and symptomatic treatment according to need. RT-PCR test done every 3rd, 5th and 7th day and Thyroid hormone level (TSH,T3, T4, FT4) at 4th week for follow up. Results: The group of patients used 1% PVP-I have shown tremendously reduced mortality, morbidity and hospital as well as financial burden in this covid situation. Conclusion: Administration of 1% PVP-I as mouthwash/gargle, nasal or eye drop is simple, rapid and cost effective in reduction of mortality and morbidity by COVID-19. Bioresearch Commu. 7(1): 919-923, 2021 (January)